Company Overview
Company Type: Public Company
Website: www.xenon-pharma.com
Number of Employees: 208
Ticker: XENE (NasdaqGM)
Year Founded: 1996


Business Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company’s product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
0.2
Market Capitalization
2,952.0
TEV/Total Revenue
NM
EBITDA
(253.2)
Total Enterprise Value
2,071.9
TEV/EBITDA
NM
EBIT
(255.7)
Cash & ST Invst.
741.3
P/Diluted EPS Before Extra
NM
Net Income
(224.9)
Total Debt
15.8
Price/Tang BV
3.3x
Capital Expenditure
(8.9)
Total Assets
940.9
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023


Estimates Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS Normalized
(1.03)
(1.10)
(3.98)
(4.49)
(4.30)
Revenue (mm)
1.86
2.58
4.44
8.43
4.44
EBITDA (mm)
(65.22)
(64.29)
(285.44)
(295.44)
(290.44)

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/REV
NM
TEV/EBITDA
NM
P/BV
4.01x

Non-Periodic Estimates

Recommendation
Buy (1.27)
Target Price
71.80
Potential Upside
48.61%


Key Professionals
Name
Title
Mortimer, Ian C.
President, CEO & Director
Aulin, Sherry 
Chief Financial Officer
DiFabio, Andrea 
Chief Legal Officer & Corporate Secretary
McCloskey, Shelley 
Executive Vice President of Human Resources
Empfield, James R.
Executive Vice President of Drug Discovery
Grant, Sheila M.
Executive Vice President of R&D Operations
Kenney, Christopher John
Chief Medical Officer
Sherrington, Robin P.
Executive Vice President of Strategy & Innovation
Von Seggern, Christopher E.
Chief Commercial Officer

Key Board Members
Name
Title
Pimstone, Simon N.
Chairman of the Board
Mortimer, Ian C.
President, CEO & Director
Azab, Mohammad 
Independent Director
Gannon, Steven R.
Independent Director
Patou, Gary 
Independent Director
Svoronos, Dawn A.
Lead Independent Director
Cannon, Gillian M.
Director
Garofalo, Elizabeth A.
Independent Director
Gover, Justin D.
Director
Machado, C. Patrick
Independent Director


Primary Industry Classification
Biotechnology


Primary Office Location
3650 Gilmore Way Suite 200 | Burnaby, BC | V5G 4W8 | Canada
Phone: 604 484 3300   Fax: 604 484 3450

Current and Pending Investors
Avoro Capital Advisors LLC, BVF Partners L.P., Fidelity Investments, Five Corners Capital Inc., Genome British Columbia, Genome Canada, Genome Quebec, Investment Arm, GrowthWorks Ltd., Invesco Private Capital, Inc., Lipoterx Ltd., MX Associates LLP, Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), Novo Holdings A/S, Novo Nordisk A/S (CPSE:NOVO B), OrbiMed Advisors LLC, Pfizer Inc. (NYSE:PFE), RBC Capital Partners, Roche Finanz AG, Roche Holding AG (SWX:ROG), SVB Silicon Valley Bank, Investment Arm

Prior Investors
Amorchem, Caisse de dépôt et placement du Québec, GeneChem Technologies Venture Fund, L.P., InterWest Partners LLC, J.P. Morgan Partners, LLC, Panorama Capital, Roche Venture Fund, Roche Venture Fund, T2C2 Capital, T2C2/Bio, L.P., Takeda Ventures, Inc., Ventures West 7 Fund, Ventures West Capital Ltd.

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 48.31
Market Cap (mm)
3,099.2
Open
 46.08
Shares Out. (mm)
64.1
Previous Close
 48.31
Float %
92.0%
Change on Day
2.29
Shares Sold Short (mm)
2.8
Change % on Day
5.0%
Dividend Yield %
-
Day High/Low
 48.66/ 45.68
Diluted EPS Excl. Extra Items
(3.54)
52 wk High/Low
 60.10/ 43.67
P/Diluted EPS Before Extra
NM
Volume (mm)
0.70
Avg 3M Dly Vlm (mm)
0.35
Beta 5Y
1.30


 
Delayed Quote** | Last Updated on Oct-05-2023 12:00 AM (GMT-5)
NasdaqGM:XENE - Common Stock


Index Membership
S&P Americas Under USD3 Billion Index;S&P Americas BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Americas BMI Growth Index;S&P Americas BMI Value Index;S&P Americas SmallCap Health Care (Sector) Index;S&P Canada BMI Value Health Care (Sector) Index;S&P Canada SmallCap Index;S&P Canada SmallCap Growth Index;S&P Canada SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Americas BMI Index;S&P Americas BMI Health Care (Sector) Index;S&P Americas SmallCap Index;S&P Developed Between USD2 Billion and USD10 Billion Index;S&P Developed BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Americas Between USD500 Million and USD2.5 Billion Index;S&P Canada BMI Growth Index;S&P Americas SmallCap Growth Index;S&P Americas Between USD1 Billion and USD5 Billion Index;S&P Americas Between USD2 Billion and USD10 Billion Index;S&P Americas SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Americas SmallCap Value Index;S&P Developed Ex-Australia Between USD1 Billion and USD5 Billion Index;S&P DM Ex-Australia SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Canada SmallCap Health Care (Sector) Index;S&P Canada SmallCap Value Health Care (Sector) Index;S&P Canada Under USD3 Billion Index;S&P Canada BMI Health Care (Sector) Index;S&P Developed BMI Value Index;S&P Developed Ex-Asia-Pacific BMI Growth Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific BMI Value Health Care (Sector) Index;S&P Developed Ex-Australia Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-Europe Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-Europe BMI Growth Index;S&P Developed Ex-Europe BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Europe SmallCap Health Care (Sector) Index;S&P Developed BMI Index;S&P Developed Ex-Asia-Pacific BMI Growth Index;S&P Developed Ex-Australia BMI Index;S&P Developed Ex-Eurozone Between USD2 Billion and USD10 Billion Index;S&P Developed Ex-Eurozone BMI Growth Index;S&P Developed Ex-Eurozone SmallCap Index;S&P Developed Ex-Eurozone SmallCap Health Care (Sector) Index;S&P Developed Between USD1 Billion and USD5 Billion Index;S&P Developed BMI Growth Index;S&P Developed Ex-Asia-Pacific BMI Index;S&P DM Ex-Asia-Pacific BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Asia-Pacific BMI Value Index;S&P Developed Ex-Australia SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Australia Under USD3 Billion Index;S&P Developed Ex-Europe BMI Growth Health Care (Sector) Index;S&P Developed Ex-Australia SmallCap Growth Index;S&P Developed Ex-Europe Between USD2 Billion and USD10 Billion Index;S&P Developed Ex-Switzerland Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-Switzerland BMI Index;S&P Developed Ex-Switzerland SmallCap Health Care (Sector) Index;S&P Developed Ex-Switzerland SmallCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-Switzerland Under USD3 Billion Index;S&P Developed Ex-U.K. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Asia-Pacific SmallCap Growth Index;S&P Developed Ex-Asia-Pacific SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Eurozone Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-Eurozone BMI Index;S&P Developed Ex-Eurozone SmallCap Value Index;S&P Developed Ex-Japan BMI Index;S&P Developed Ex-Japan BMI Growth Health Care (Sector) Index;S&P Developed Ex-Japan BMI Health Care (Sector) Index;S&P Developed Ex-Australia BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Australia SmallCap Value Index;S&P Developed Ex-Japan SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Switzerland BMI Health Care (Sector) Index;S&P Developed Ex-Switzerland SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Switzerland SmallCap Value Health Care (Sector) Index;S&P Developed Ex-Europe SmallCap Index;S&P Developed Ex-Eurozone Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-Eurozone BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Asia-Pacific Under USD3 Billion Index;S&P Developed Ex-Australia Between USD2 Billion and USD10 Billion Index;S&P Developed Ex-Australia BMI Growth Index;S&P Developed Ex-Australia BMI Growth Health Care (Sector) Index;S&P Developed Ex-Australia BMI Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan BMI Growth Index;S&P DM Ex-U.S. & Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.S. & Japan SmallCap Value Index;S&P Developed Ex-Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.K. Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-U.K. Between USD2 Billion and USD10 Billion Index;S&P Developed Ex-U.K. BMI Growth Health Care (Sector) Index;S&P Developed Ex-U.K. BMI Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan SmallCap Growth Index;S&P Developed Ex-U.S. & Japan SmallCap Health Care (Sector) Index;S&P Developed Ex-Europe Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-Europe SmallCap Value Health Care (Sector) Index;S&P Developed Ex-Eurozone BMI Value Health Care (Sector) Index;S&P Developed Ex-U.S. Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-U.S. SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-U.S. Under USD3 Billion Index;S&P Developed Ex-U.S. & U.K. Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-U.S. & U.K. BMI Index;S&P Developed Ex-U.S. & U.K. BMI Growth Index;S&P Developed Ex-U.S. & U.K. SmallCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-U.S. & U.K. Under USD3 Billion Index;S&P Developed Ex-U.S. Between USD2 Billion and USD10 Billion Index;S&P Developed Ex-U.S. BMI Growth Health Care (Sector) Index;S&P Developed SmallCap Value Health Care (Sector) Index;S&P Developed Under USD3 Billion Index;S&P Developed Ex-U.S. SmallCap Health Care (Sector) Index;S&P Developed SmallCap Index;S&P Developed Ex-Eurozone SmallCap Growth Index;S&P DM Ex-Eurozone SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Japan SmallCap Health Care (Sector) Index;S&P DM Ex-Japan SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Canada Between USD500 Million and USD2.5 Billion Index;S&P Canada BMI Growth Health Care (Sector) Index;S&P Developed Ex-Europe BMI Index;S&P Developed Ex-U.K. BMI Value Health Care (Sector) Index;S&P Developed Ex-U.K. SmallCap Index;S&P Developed Ex-U.K. SmallCap Value Index;S&P Developed Ex-U.S. & Japan Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-U.S. & Japan BMI Index;S&P Developed Ex-U.S. & Japan BMI Growth Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan BMI Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan SmallCap Value Health Care (Sector) Index;S&P Developed Ex-U.K. BMI Growth Index;S&P Developed Ex-U.K. BMI Value Index;S&P Developed Ex-U.K. SmallCap Health Care (Sector) Index;S&P Developed Between USD500 Million and USD2.5 Billion Index;S&P Developed BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific SmallCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-Australia BMI Value Health Care (Sector) Index;S&P Developed Ex-Europe SmallCap Growth Index;S&P Developed Ex-Eurozone BMI Growth Health Care (Sector) Index;S&P Developed Ex-Eurozone Under USD3 Billion Index;S&P Developed Ex-Japan Between USD2 Billion and USD10 Billion Index;S&P Developed Ex-Japan BMI Value Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan BMI Value Index;S&P Developed Ex-U.S. & U.K. SmallCap Index;S&P Developed Ex-U.S. Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-U.S. BMI Growth Index;S&P Developed Ex-U.S. BMI Value Health Care (Sector) Index;S&P Developed Ex-U.S. & U.K. Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-U.S. & U.K. BMI Growth Health Care (Sector) Index;S&P DM Ex-U.S. & U.K. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.S. & U.K. SmallCap Health Care (Sector) Index;S&P Developed Ex-U.S. & U.K. SmallCap Value Health Care (Sector) Index;S&P Developed Ex-U.S. BMI Index;S&P Developed Ex-U.S. BMI Health Care (Sector) Index;S&P Developed Ex-Australia SmallCap Health Care (Sector) Index;S&P Developed Ex-U.S. SmallCap Growth Index;S&P Global Between USD1 Billion and USD5 Billion Index;S&P Global BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Pan Asia Between USD2 Billion and USD10 Billion Index;S&P Global Ex-Pan Asia BMI Health Care (Sector) Index;S&P Global Ex-Pan Asia BMI Value Index;S&P Global Ex-Pan Asia SmallCap Pharmaceuticals, Biotech & Life Sciences (Industry Group) Index;S&P Developed Ex-Europe BMI Value Index;S&P Developed Ex-Europe SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Europe Under USD3 Billion Index;S&P Developed Ex-Eurozone BMI Value Index;S&P Developed Ex-Japan SmallCap Index;S&P Developed Ex-Switzerland Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-Switzerland BMI Growth Index;S&P Developed Ex-Switzerland BMI Growth Health Care (Sector) Index;S&P DM Ex-Switzerland BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Switzerland BMI Value Index;S&P Global Ex-U.S. BMI Health Care (Sector) Index;S&P Developed Ex-U.S. SmallCap Value Index;S&P Developed Ex-Japan Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-Japan Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-Japan SmallCap Growth Index;S&P Developed Ex-Japan SmallCap Value Index;S&P Developed Ex-Switzerland SmallCap Index;S&P Developed Ex-Switzerland SmallCap Growth Index;S&P Developed Ex-U.K. SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.K. SmallCap Value Health Care (Sector) Index;S&P Developed Ex-U.K. Under USD3 Billion Index;S&P Developed Ex-U.S. & Japan Between USD2 Billion and USD10 Billion Index;S&P Canada Between USD1 Billion and USD5 Billion Index;S&P Canada BMI Index;S&P Canada BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Canada BMI Value Index;S&P Developed Ex-U.S. & Japan SmallCap Index;S&P Developed Ex-U.S. & U.K. SmallCap Growth Index;S&P Developed BMI Growth Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-Asia-Pacific Between USD2 Billion and USD10 Billion Index;S&P Developed Ex-Asia-Pacific SmallCap Index;S&P Developed Ex-Asia-Pacific SmallCap Value Index;S&P Developed Ex-Asia-Pacific SmallCap Value Health Care (Sector) Index;S&P Developed Ex-Australia BMI Value Index;S&P Developed Ex-U.K. SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan BMI Value Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan SmallCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-U.S. & U.K. Between USD2 Billion and USD10 Billion Index;S&P Developed Ex-U.S. & U.K. BMI Health Care (Sector) Index;S&P Developed Ex-U.S. & U.K. SmallCap Value Index;S&P Developed Ex-Australia SmallCap Index;S&P Developed Ex-Europe BMI Health Care (Sector) Index;S&P Developed Ex-Europe BMI Value Health Care (Sector) Index;S&P Developed Ex-Eurozone BMI Health Care (Sector) Index;S&P Global Between USD2 Billion and USD10 Billion Index;S&P Global Ex-Pan Asia BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-U.S. BMI Growth Index;S&P Developed Ex-Japan Under USD3 Billion Index;S&P Developed Ex-Switzerland Between USD2 Billion and USD10 Billion Index;S&P Developed Ex-U.K. Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-U.K. BMI Index;S&P Global Between USD500 Million and USD2.5 Billion Index;S&P Global Ex-Japan Between USD1 Billion and USD5 Billion Index;S&P Global Ex-Japan Between USD500 Million and USD2.5 Billion Index;S&P Global Ex-Japan BMI Value Index;S&P Global BMI Index;S&P Developed Ex-U.S. SmallCap Value Health Care (Sector) Index;S&P Global Ex-Japan Under USD3 Billion Index;S&P Global Ex-Japan BMI Health Care (Sector) Index;S&P Global Ex-Pan Asia Between USD500 Million and USD2.5 Billion Index;S&P Global Ex-Pan Asia SmallCap Growth Index;S&P Global Ex-U.S. Between USD2 Billion and USD10 Billion Index;S&P Global Ex-U.S. BMI Value Index;S&P Global Ex-U.S. SmallCap Growth Index;S&P Global Ex-U.S. SmallCap Value Index;S&P Global SmallCap Health Care (Sector) Index;S&P Developed Ex-U.S. BMI Value Index;S&P Developed Ex-U.S. SmallCap Index;S&P Global Ex-U.S. SmallCap Health Care (Sector) Index;S&P Global Ex-U.S. Under USD3 Billion Index;S&P Global Under USD3 Billion Index;S&P Global SmallCap Index;S&P Global SmallCap Growth Index;S&P North America BMI Value Health Care (Sector) Index;S&P North America SmallCap Index;S&P North America SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Japan SmallCap Index;S&P Global Ex-Pan Asia SmallCap Health Care (Sector) Index;S&P Global Ex-Pan Asia SmallCap Value Index;S&P Global Ex-U.S. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-U.S. SmallCap Index;S&P North America BMI Index;S&P Global SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P North America SmallCap Value Index;S&P Global Ex-Japan SmallCap Value Index;S&P Global Ex-Pan Asia Between USD1 Billion and USD5 Billion Index;S&P Global Ex-Pan Asia Under USD3 Billion Index;S&P Global Ex-U.S. Between USD500 Million and USD2.5 Billion Index;S&P Global Ex-U.S. BMI Index;S&P Global Ex-U.S. SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.S. & Japan Under USD3 Billion Index;S&P North America SmallCap Growth Health Care (Sector) Index;S&P North America BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P North America BMI Value Index;S&P North America SmallCap Health Care (Sector) Index;S&P Developed Ex-U.S. & U.K. SmallCap Growth Health Care (Sector) Index;S&P Developed SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P North America Under USD3 Billion Index;S&P Global BMI Growth Index;S&P Global Ex-Japan BMI Growth Index;S&P Global Ex-Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Japan SmallCap Growth Index;S&P Global Ex-Pan Asia BMI Index;S&P Global Ex-Pan Asia BMI Growth Index;S&P North America Between USD2 Billion and USD10 Billion Index;S&P North America BMI Growth Index;S&P North America BMI Growth Health Care (Sector) Index;S&P North America BMI Health Care (Sector) Index;S&P North America SmallCap Value Health Care (Sector) Index;S&P Canada Between USD2 Billion and USD10 Billion Index;S&P Canada SmallCap Growth Health Care (Sector) Index;S&P Canada SmallCap Value Index;S&P Developed BMI Value Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-Asia-Pacific BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific SmallCap Health Care (Sector) Index;S&P Developed Ex-Australia SmallCap Value Health Care (Sector) Index;S&P DM Ex-Europe SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Europe SmallCap Value Index;S&P Developed Ex-Eurozone SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Eurozone SmallCap Value Health Care (Sector) Index;S&P Developed Ex-Japan BMI Growth Index;S&P Developed Ex-Japan BMI Value Index;S&P Developed Ex-Japan SmallCap Value Health Care (Sector) Index;S&P Developed Ex-Switzerland BMI Value Health Care (Sector) Index;S&P Developed Ex-Switzerland SmallCap Value Index;S&P Developed Ex-U.K. SmallCap Growth Index;S&P Developed Ex-U.S. & Japan Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-U.S. & U.K. BMI Value Index;S&P Developed Ex-U.S. & U.K. BMI Value Health Care (Sector) Index;S&P Developed Ex-U.S. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.S. SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed SmallCap Growth Index;S&P Developed SmallCap Growth Health Care (Sector) Index;S&P Developed SmallCap Health Care (Sector) Index;S&P Developed SmallCap Value Index;S&P Global BMI Health Care (Sector) Index;S&P Global BMI Value Index;S&P Global Ex-Japan Between USD2 Billion and USD10 Billion Index;S&P Global Ex-Japan BMI Index;S&P Global Ex-Japan SmallCap Health Care (Sector) Index;S&P Global Ex-Japan SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Pan Asia SmallCap Index;S&P Global Ex-U.S. Between USD1 Billion and USD5 Billion Index;S&P Global SmallCap Value Index;S&P North America Between USD1 Billion and USD5 Billion Index;S&P North America Between USD500 Million and USD2.5 Billion Index;S&P North America SmallCap Growth Index;S&P Developed Ex-Japan BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Eurozone BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-U.S. & UK BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P North America BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-U.S. & Japan BMI Growth Pharm, Biotech & Life Sciences (Industry Group) Index;S&P Canada BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Asia Pacific BMI Growth Pharm, Biotech & Life Sciences (Industry Group) Index;S&P Developed Ex-Switzerland BMI Growth Pharm, Biotech & Life Sciences (Industry Group) Index;S&P Developed Ex-Europe BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-UK BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Australia BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Eurozone BMI Value Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-U.S. BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-U.S. & Japan BMI Value Pharm, Biotech & Life Sciences (Industry Group) Index;S&P Developed Ex-Asia Pacific BMI Value Pharm, Biotech & Life Sciences (Industry Group) Index;S&P Developed Ex-Australia BMI Value Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-U.S. & UK BMI Value Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Switzerland BMI Value Pharm, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-UK BMI Value Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Europe BMI Value Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-U.S. BMI Value Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Canada BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)  Index;S&P North America BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Japan BMI Value Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Israel BMI Growth Index;S&P Developed Ex-Israel BMI Growth Health Care (Sector) Index;S&P Developed Ex-Israel BMI Index;S&P Developed Ex-Israel BMI Health Care (Sector) Index;S&P Developed Ex-Israel BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Israel BMI Value Index;S&P Developed Ex-Israel BMI Value Health Care (Sector) Index;S&P Developed Ex-Israel SmallCap Growth Index;S&P Developed Ex-Israel SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Israel SmallCap Index;S&P Developed Ex-Israel SmallCap Health Care (Sector) Index;S&P DM Ex-Israel SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Israel SmallCap Value Index;S&P Developed Ex-Israel SmallCap Value Health Care (Sector) Index;S&P Developed Ex-Israel BMI Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-Israel BMI Between USD2 Billion and USD10 Billion Index;S&P Developed Ex-Israel BMI Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-Israel Under USD3 Billion Index;S&P Global Ex-Australia BMI Index;S&P Global Ex-Europe BMI Index;S&P Global Ex-United Kingdom BMI Index;S&P Developed Ex-Continental Europe BMI Index;S&P Developed Ex-Japan, Ex-South Korea BMI Index;S&P Americas Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Canada Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Asia-Pacific Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Australia Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Europe Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Eurozone Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Israel Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Japan Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Switzerland Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-U.K. Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-U.S. & Japan Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-U.S. & U.K. Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-U.S. Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Global Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Global Ex-Japan Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Global Ex-Pan Asia Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Global Ex-U.S. Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P North America Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed BMI Ex-U.S. & Korea Index;S&P DM Ex. Japan SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex. Japan SmallCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-Australia SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group;S&P DM Ex-Israel SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subsect;S&P Developed Ex-U.K. SmallCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & Japan SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subsec;S&P Developed Ex-U.S. & U.K. SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subsect;S&P Canada SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Canada SmallCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia-Pacific SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subsec;S&P DM Ex-Australia SmallCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia-Pacific SmallCap Value Pharmaceuticals, Biotechnology & Life Sciences (Subsect;S&P DM Ex-Europe SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-Eurozone SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-Eurozone SmallCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Israel BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Israel BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-U.S. SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. SmallCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-Israel SmallCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & U.K. SmallCap Value Pharmaceuticals, Biotechnology & Life Sciences (Subsecto;S&P Developed SmallCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland SmallCap Value Pharmaceuticals, Biotechnology & Life Sciences (Subsecto;S&P North America SmallCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-U.K. SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-Europe SmallCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & Japan SmallCap Value Pharmaceuticals, Biotechnology & Life Sciences (Subsect;S&P North America SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Global Ex-Australia & New Zealand Between USD1 Billion and USD5 Billion;S&P Global Ex-China A BMI;S&P Global Ex-China A SmallCap;S&P Global Ex-U.S. & China A BMI;S&P Global Ex-U.S. & China A SmallCap;S&P Developed Ex-Korea BMI;S&P Developed Ex-U.S. & Korea SmallCap;S&P Developed Ex-Korea SmallCap;S&P Canada BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Canada BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia Pacific BMI Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Japan SmallCap Val Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland BMI Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Australia BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & Japan SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & UK BMI Grwth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia Pacific SmallCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Australia SmallCap Growth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Europe BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Europe BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-UK SmallCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Israel SmallCap Val Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland SmallCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Europe SmallCap Val Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone SmallCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Japan SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & UK BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Israel SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Australia BMI Grwth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & Japan SmallCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Europe SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-UK BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P North America BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-UK BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & UK SmallCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-UK SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Japan BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia Pacific BMI Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & Japan BMI Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. SmallCap Grwth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia Pacific SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Australia SmallCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Japan BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland BMI Val Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & Japan BMI Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & UK SmallCap Growth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P North America BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Korea BMI Growth;S&P Developed Ex-Korea BMI Value


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
QuantaNova Canada Limited
QuantaNova Canada Limited was acquired by Xenon Genetics, Inc. on 10/24/2001. QuantaNova Canada is a genomics company that researches and develops lipid metabolism drug discovery technology programs, drug screening and diagnostic assays, biological materials, and radiochemicals. It was formerly known as Efamol Research Inc. The company was founded in 1978 and is based in Kentville, Canada.

United States and Canada
Biotechnology
-
-
-
RGS Genome Inc.
As of December 31, 2000, RGS Genome Inc. was acquired by Xenon Pharmaceuticals Inc. RGS Genome Inc. is a clinical genomics company. The company is based in Montreal, Canada.

United States and Canada
Biotechnology
-
-
-
Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS)
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California.

United States and Canada
Biotechnology
631.00
2,971.00
1,490.00
Xenon Pharmaceuticals Usa Inc

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jun-22-2022
Jun-22-2022
Public Offering
Target
Xenon Pharmaceuticals Inc. (NasdaqGM:XENE)


250.00
Jun-2-2022
-
Shelf Registration
Target
Xenon Pharmaceuticals Inc. (NasdaqGM:XENE)


141.40
Jan-11-2022
-
Private Placement
Target
Xenon Pharmaceuticals Inc. (NasdaqGM:XENE)
Neurocrine Biosciences, Inc. (NasdaqGS:NBIX)

8.25
Oct-4-2021
Oct-5-2021
Public Offering
Target
Xenon Pharmaceuticals Inc. (NasdaqGM:XENE)


300.00
Oct-4-2021
-
Shelf Registration
Target
Xenon Pharmaceuticals Inc. (NasdaqGM:XENE)


-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-20-2023
Company Conference Presentations
Xenon Pharmaceuticals Inc. Presents at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit, Sep-20-2023 04:20 PM
Sep-19-2023
Special Calls
Xenon Pharmaceuticals Inc. - Special Call
Sep-06-2023
Company Conference Presentations
Xenon Pharmaceuticals Inc. Presents at Wells Fargo Securities Healthcare Conference 2023, Sep-06-2023 02:15 PM
Sep-04-2023
Product-Related Announcements
Xenon Pharmaceuticals Inc. Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress
Aug-09-2023
Earnings Calls
Xenon Pharmaceuticals Inc., Q2 2023 Earnings Call, Aug 09, 2023


Advisors
Most Recent Auditor
KPMG Limited
Private Placement Advisors
Chase H&Q, McCarthy Tétrault LLP, Pepper Hamilton LLP, Wilson Sonsini Goodrich & Rosati, P.C.
Public Offering Advisors
Blake, Cassels & Graydon LLP, Bloom Burton Securities Inc., Chen & Associates (in association with Wilson Sonsini Goodrich & Rosati, Professional Corporation), KPMG LLP, KPMG LLP (Canada), McCarthy Tétrault LLP, Wilson Sonsini Goodrich & Rosati, P.C.


Most Recent Auditor
KPMG LLP - Klynveld Peat Marwick Goerdeler


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

03:57 AM
XENE
Xenon Pharmaceuticals Inc 2023_10_05
Reports
14
ValuEngine, Inc.

Oct 02, 2023 05:51 AM
XENE
ValuEngine Rating and Forecast Report for XENE
Reports
11
The Economy Matters

Oct 02, 2023 05:17 AM
XENE
The Economy Matters
Reports
8
CFRA Equity Research

Oct 01, 2023 01:54 PM
XENE
Xenon Pharmaceuticals Inc.
Reports
9
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Sep 24, 2023 06:00 PM
XENE
Is Xenon Pharmaceuticals Inc for Long-Term Investors?
Ratings Change*
12
RBC Capital Markets
Davis, Luke
Sep 22, 2023 03:03 AM
XENE
XENE: Takeaways from the Road: '1101 Has A Shot In MDD, With Core, Differentiated Epilepsy Program On Track
Reports
11
J.P. Morgan
Romero, Tessa Thomas
Sep 20, 2023 10:51 PM
XENE
Xenon Pharmaceuticals: Key Takeaways From Our CEO Conference Call
Notes
7
William Blair & Company L.L.C.
Lugo, Timothy Francis
Sep 20, 2023 03:36 AM
XENE
MDD KOL Webinar Highlights Unmet Need and Rationale for XEN1101 Ahead of X-NOVA Top-Line Readout Late November/Early December
Reports
6
RBC Capital Markets
Davis, Luke
Sep 19, 2023 05:12 PM
XENE
XENE: Takeaways from Virtual MDD Event: Ph.II Ezogabine Data and Unmet Need Create Attractive Setup
Reports
11
Stifel
Matteis, Paul Andrew
Sep 19, 2023 02:53 PM
XENE
XENE MDD KOL Event: Continue To Like The Risk/Reward Ahead of X-NOVA, Data on Track For Late November/Mid December
Notes
5


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


FMR LLC

5,188,707

8.09

239.6

Jun-30-2023


Avoro Capital Advisors LLC

4,900,000

7.64

226.3

Jun-30-2023


Driehaus Capital Management LLC

4,760,853

7.42

219.9

Jun-30-2023


Capital Research and Management Company

4,596,965

7.17

212.3

Jun-30-2023


Polar Capital Holdings Plc

3,022,071

4.71

139.6

Jun-30-2023


Marshall Wace LLP

2,320,419

3.62

107.2

Jun-30-2023


Pictet Asset Management Limited

2,032,730

3.17

93.9

Jun-30-2023


Lord, Abbett & Co. LLC

1,958,540

3.05

90.5

Jun-30-2023


Commodore Capital LP

1,845,000

2.88

85.2

Jun-30-2023


Braidwell LP

1,828,353

2.85

84.4

Jun-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Polar Capital Holdings Plc
3,022,071
3,022,071
Wellington Management Group LLP
1,051,051
803,614
Invesco Ltd.
685,300
683,616
Fiera Capital Corporation
549,341
549,341
Avidity Partners Management, L.P.
481,300
481,300

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Logos Global Management, L.P.
275,000
(625,000)
Perceptive Advisors LLC
1,223,377
(608,797)
Citadel Advisors LLC
501,012
(370,222)
Point72 Asset Management, L.P.
148,208
(358,371)
Braidwell LP
1,828,353
(308,757)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Glybera, Licensing of NBI-921352, Licensing of PCRX301, Licensing of XEN393, Licensing of XPC’391, Licensing of XPC’535, NBI-921352 (Future), PCRX301 (Future), XEN1101 (Future), XEN393 (Future), XEN496 (Future), XPC’391 (Future), XPC’535 (Future)


Upcoming Events
Date/Time
Type
Nov-03-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-14-2023
-
Xenon Pharmaceuticals Inc. (NasdaqGM:XENE)
SEDAR
News Releases
186 KB
Sep-12-2023
-
Xenon Pharmaceuticals Inc. (NasdaqGM:XENE)
SEDAR
News Releases
166 KB
Sep-04-2023
-
Xenon Pharmaceuticals Inc. (NasdaqGM:XENE)
SEDAR
News Releases
119 KB
Aug-31-2023
-
Xenon Pharmaceuticals Inc. (NasdaqGM:XENE)
SEDAR
News Releases
153 KB
Aug-18-2023
-
Xenon Pharmaceuticals Inc. (NasdaqGM:XENE)
SEDAR
Material Change Report
80 KB
Aug-09-2023
-
Xenon Pharmaceuticals Inc. (NasdaqGM:XENE)
SEDAR
News Releases
138 KB
Aug-09-2023
Jun-30-2023
Xenon Pharmaceuticals Inc. (NasdaqGM:XENE)
SEDAR
Interim Financial Statements
617 KB
Aug-09-2023
Jun-30-2023
Xenon Pharmaceuticals Inc. (NasdaqGM:XENE)
SEC
10-Q
9 MB
Aug-09-2023
Aug-09-2023
Xenon Pharmaceuticals Inc. (NasdaqGM:XENE)
SEC
8-K (2.01, 7.01, 9.01)
471 KB
Aug-08-2023
-
Xenon Pharmaceuticals Inc. (NasdaqGM:XENE)
SEDAR
News Releases
84 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Svoronos, Dawn A. (Lead Independent Director)
Aug-24-2023
Common Shares
(25,000)
(1,329,103)
Open Market Disposition
(50.00)
Form 4
Pimstone FRCPC, M.B. ChB., M.D., Ph.D., Simon N. (Chairman of the Board)
May-31-2023 - Jun-01-2023
Common Shares
(134,153)
(4,302,263)
Derivative Exercise and Sale
-
Form 4
-
May-31-2023
Common Shares
29,835
403,710
Derivative Exercise
-
Form 4
-
May-31-2023
Common Shares
(6,165)
(324,962)
Sale
-
Form 4
-
May-31-2023
Common Shares
(23,670)
(1,261,972)
Sale
-
Form 4
-
May-31-2023
Common Shares
50,000
1,219,890
Derivative Exercise
-
Form 4
-
May-31-2023
Common Shares
(23,144)
(1,219,938)
Sale
-
Form 4
-
May-31-2023
Common Shares
(26,856)
(1,427,407)
Sale
-
Form 4
-
Jun-01-2023
Common Shares
9,318
98,437
Derivative Exercise
-
Form 4
-
Jun-01-2023
Common Shares
(1,860)
(98,451)
Sale
-
Form 4
-
Jun-01-2023
Common Shares
(7,458)
(399,264)
Sale
-
Form 4
-
Jun-01-2023
Common Shares
45,000
1,097,901
Derivative Exercise
-
Form 4
-
Jun-01-2023
Common Shares
(20,745)
(1,098,045)
Sale
-
Form 4
-
Jun-01-2023
Common Shares
(24,255)
(1,292,161)
Sale
-
Form 4
Pimstone FRCPC, M.B. ChB., M.D., Ph.D., Simon N. (Chairman of the Board)
May-30-2023 - May-31-2023
Common Shares
(49,006)
(2,632,149)
Open Market Disposition
(89.09)
Form 4
-
May-30-2023
Common Shares
(18,006)
(955,542)
Open Market Disposition
-
Form 4
-
May-30-2023
Common Shares
(19,000)
(1,041,440)
Open Market Disposition
-
Form 4
-
May-31-2023
Common Shares
(12,000)
(635,167)
Open Market Disposition
-
Form 4
Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA, Ian C. (President, CEO & Director)
May-24-2023
Common Shares
(44,038)
(1,930,472)
Derivative Exercise and Sale
-
Form 4
-
May-24-2023
Common Shares
24,379
316,152
Derivative Exercise
-
Form 4
-
May-24-2023
Common Shares
(7,310)
(420,162)
Sale
-
Form 4
-
May-24-2023
Common Shares
(17,069)
(971,707)
Sale
-
Form 4
-
May-24-2023
Common Shares
17,081
231,130
Derivative Exercise
-
Form 4
-
May-24-2023
Common Shares
(3,902)
(224,278)
Sale
-
Form 4
-
May-24-2023
Common Shares
(13,179)
(748,989)
Sale
-
Form 4
-
May-24-2023
Common Shares
2,578
34,884
Derivative Exercise
-
Form 4
-
May-24-2023
Common Shares
(1,171)
(67,306)
Sale
-
Form 4
-
May-24-2023
Common Shares
(1,407)
(80,195)
Sale
-
Form 4
Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA, Ian C. (President, CEO & Director)
May-24-2023
Common Shares
25,302
332,114
Derivative Exercise and Retained Stock
124.64
Form 4
-
May-24-2023
Common Shares
18,213
236,190
Derivative Exercise and Retained Stock
-
Form 4
-
May-24-2023
Common Shares
3,495
47,292
Derivative Exercise and Retained Stock
-
Form 4
-
May-24-2023
Common Shares
3,594
48,632
Derivative Exercise and Retained Stock
-
Form 4
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Pimstone, Simon N.
Chairman of the Board
604 484 3300
604 484 3450
spimstone@xenon-pharma.com
Mortimer, Ian C.
President, CEO & Director
604 484 3300
604 484 3450

Azab, Mohammad 
Independent Director
604 484 3300
604 484 3450

Gannon, Steven R.
Independent Director
604 484 3300
604 484 3450

Patou, Gary 
Independent Director
604 484 3300
604 484 3450

Svoronos, Dawn A.
Lead Independent Director
604 484 3300
604 484 3450

Cannon, Gillian M.
Director
604 484 3300
604 484 3450

Garofalo, Elizabeth A.
Independent Director
604 484 3300
604 484 3450

Gover, Justin D.
Director
604 484 3300
604 484 3450

Machado, C. Patrick
Independent Director
604 484 3300
604 484 3450

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Mortimer, Ian C.
President, CEO & Director
604 484 3300
604 484 3450

Aulin, Sherry 
Chief Financial Officer
604 484 3300
604 484 3450

DiFabio, Andrea 
Chief Legal Officer & Corporate Secretary
604 484 3300
604 484 3450

McCloskey, Shelley 
Executive Vice President of Human Resources
604 484 3300
604 484 3450

Empfield, James R.
Executive Vice President of Drug Discovery
604 484 3300
604 484 3450

Grant, Sheila M.
Executive Vice President of R&D Operations
604 484 3300
604 484 3450

Kenney, Christopher John
Chief Medical Officer
604 484 3300
604 484 3450

Sherrington, Robin P.
Executive Vice President of Strategy & Innovation
604 484 3300
604 484 3450
rsherrington@xenon-pharma.com
Von Seggern, Christopher E.
Chief Commercial Officer
604 484 3300
604 484 3450
chris.vonseggern@clearviewhcp.com
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
